Kayla Bone
Family · Fredericktown, MONPI 1336875830
Payments from drug & device makers
Across 100 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$641
- Lundbeck LLC$99
- GSK$84
- Novo Nordisk$80
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$75
- Sumitomo Pharma America, Inc.$59
- plus $496 from 18 others
What the payments were for
- Food & beverage$1,534100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,534 in reported general payments places this provider in the 75th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 63 | $68,437 |
| OzempicSemaglutide | 61 | $59,410 |
| EliquisApixaban | 118 | $55,972 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $50,644 |
| LinzessLinaclotide | 55 | $29,290 |
| JardianceEmpagliflozin | 49 | $26,008 |
| MounjaroTirzepatide | 24 | $24,464 |
| GemtesaVibegron | 83 | $20,645 |
| MyrbetriqMirabegron | 21 | $8,585 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $8,533 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $4,359 |
| Dexlansoprazole DrDexlansoprazole | 18 | $2,803 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 25 | $2,477 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,051 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $28 | $92,90187 claims |
| Novo NordiskOzempic | $80 | $59,41061 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $84 | $59,17886 claims |
| PfizerEliquis | $15 | $55,972118 claims |
| AbbVieLinzess | $641 | $29,29055 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $59 | $20,64583 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,812 family providers in Missouri.
Other family in Fredericktown
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.